Hasil Pencarian - Lori Parisi

  • Menampilkan 1 - 2 hasil dari 2
Perbaiki Hasil
  1. 1
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis oleh Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, José-Ángel Hernández-Rivas, Keqin Qi, Sanjay Deshpande, Lori Parisi, Michael Wang

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

    Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up oleh Martin Dreyling, Andre Goy, Georg Hess, Brad S. Kahl, José-Ángel Hernández-Rivas, Natasha Schuier, Keqin Qi, Sanjay Deshpande, Angeline Zhu, Lori Parisi, Michael L. Wang

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: